SeaStar Medical Holding Corporation has added a nationally-recognized Texas-based children’s hospital to its customer base for QUELIMMUNE therapy, approved by the FDA for pediatric patients with life-threatening AKI. Key metrics are being captured for future analysis through the SAVE Surveillance Registry. Significant data on QUELIMMUNE’s performance is being gathered through the registry, with early results expected to be presented at a medical conference later this year. SeaStar Medical is also making progress on the NEUTRALIZE-AKI pivotal trial, evaluating the therapy’s safety and efficacy in adults with AKI. An interim analysis is underway, with results anticipated in the third quarter.

Read more at GlobeNewswire: SeaStar Medical Grows Customer Base and Expands QUELIMMUNE